Kuraya M, Minarovits J, Okada H, Klein E
Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden.
Immunol Lett. 1993 Jul;37(1):35-9. doi: 10.1016/0165-2478(93)90129-p.
We studied the expression of the 20-kDa homologous restriction factor (CD59/HRF20), a complement regulatory protein, on two subsets of blood derived B cells and on Burkitt's lymphoma lines. Both low-density (activated) and high-density (resting) B cell populations expressed high levels of CD59. CD59 was detectable, however, only on a minority of cells or not at all on three Epstein-Barr virus (EBV)-negative BL lines (BL41, BL28 and DG75) and on clones of an EBV-positive BL line (Mutu) that phenotypically resembled resting B lymphocytes. On the other hand, CD59 was detected at high or medium levels on Mutu cells which had a lymphoblastoid cell-like phenotype. Expression of CD59 was upregulated by 5-azacytidine, a drug inhibiting cytosine methylation, on CD59-negative cell lines. Induction was accompanied by a partial hypomethylation in the 5' region of CD59 coding sequences.
我们研究了一种补体调节蛋白——20-kDa同源限制因子（CD59/HRF20）在血液来源的B细胞两个亚群以及伯基特淋巴瘤细胞系中的表达情况。低密度（活化）和高密度（静止）B细胞群体均表达高水平的CD59。然而，在三个爱泼斯坦-巴尔病毒（EBV）阴性的BL细胞系（BL41、BL28和DG75）以及一个表型类似于静止B淋巴细胞的EBV阳性BL细胞系（Mutu）的克隆中，仅在少数细胞上可检测到CD59，或者根本检测不到。另一方面，在具有淋巴母细胞样表型的Mutu细胞上，可检测到高水平或中等水平的CD59。在CD59阴性的细胞系中，5-氮杂胞苷（一种抑制胞嘧啶甲基化的药物）可上调CD59的表达。诱导过程伴随着CD59编码序列5'区域的部分去甲基化。
